Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]
Discontinued
Reference number: GID-TA10380
The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab for previously treated advanced hepatocellular carcinoma. Following on from an update received from company that they are no longer pursuing a Marketing Authorisation Application to the European Medicines Agency at this time, this appraisal remains suspended. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes.